Peers for comparison


Market capitalization
‪6.96 B‬ EURMid cap
−5.25 EUR
‪−336.10 M‬ EUR
0.00 EUR
‪76.37 M‬
Beta (1Y)
1.12
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Employees (FY)
69
Change (1Y)
0
Revenue / Employee (1Y)
0.00 EUR
Net income / Employee (1Y)
‪−4.87 M‬ EUR

Company info


CEO
Marc M. P. de Garidel
Website
Headquarters
Paris
Founded
2003
IPO date
Jun 26, 2015
ISIN
FR0012333284
FIGI
BBG009CG7F64
Identifiers
ISIN FR0012333284
CFI code
ESVUFN
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
Summarizing what the indicators are suggesting.
Neutral
Neutral
Neutral
An aggregate view of professional's ratings.
Neutral
Neutral
Neutral
Displays a symbol's price movements over previous years to identify recurring trends.
Weight0.02%
Market value‪111.62 M‬
Weight0.02%
Market value‪73.65 M‬
Weight0.02%
Market value‪41.85 M‬
Weight0.03%
Market value‪19.80 M‬
Weight0.05%
Market value‪17.72 M‬
Weight0.02%
Market value‪17.54 M‬
Weight0.02%
Market value‪16.38 M‬
Weight0.05%
Market value‪7.99 M‬

Explore more ETFs 

Frequently asked questions


Abivax SA is scheduled to release its next earnings report on Dec 14, 2026.

Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release

How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
ABVX stock is 5.22% volatile and has beta coefficient of 1.12.

What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable

Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like ABVX are typically less volatile than smaller companies

Track every detail on Abivax SA stock chart and check out the list of the most volatile stocks — is Abivax SA there?
To understand the ABVX stock performance, it's worth checking price changes for various periods to get the full picture:
– 1 day — −2.39%
– 1 week — −2.94%
– 1 month — −5.02%

ABVX all-time low was 3.85 EUR (Aug 23, 2016), and its highest price is 139.00 EUR (Jul 3, 2026). Find more dynamics in the Stock Heatmap and on the Abivax SA stock chart.
Abivax SA market capitalization is ‪6.96 B‬, representing the total value of all its outstanding shares (price × shares outstanding).

What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements

What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Abivax SA stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Abivax SA stacks up against other companies
The safest way to buy Abivax SA stocks is through a reliable broker. Create an account, fund it, and place a buy order.

You can trade ABVX directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart

Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
As of Nov 6, 2026, the company has 69 employees.

Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements

See our rating of the largest employers to find more opportunities.
Investing in Abivax SA depends on your goals, risk tolerance, and market conditions. It’s essential to analyze the stock before making a decision.

First, study Abivax SA financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency

Then explore our ABVX technicals – signals based on essential indicators calculations:
– Today — sell
– 1-week — neutral
– 1-month — neutral

Combine fundamental and technical analysis for better results.
Abivax SA stock ticker depends on the exchange where it’s listed. On the EURONEXT, its primary exchange, Abivax SA stocks trade under the symbol ABVX.

About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners

Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion

Learn how to find your desired assets in our Symbol Search.
ABVX earnings for the last quarter are −1.47 EUR per share, whereas the estimation was −0.80 EUR, resulting in a −83.47% surprise. The estimated earnings for the next quarter are −0.81 EUR per share.

How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one

Follow other essential metrics in Abivax SA financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk
Abivax SA revenue for the last quarter amounts to ‪1.20 M‬ EUR despite the estimated figure of ‪697.71 K‬ EUR. In the next quarter revenue is expected to reach ‪812.32 K‬ EUR.

How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous quarters and year-over-year data
– Track trends: One quarter matters less than consistent performance

Follow other essential metrics in Abivax SA financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses
Yes, you can track Abivax SA financials in yearly and quarterly reports right on TradingView.

Use our Earnings Calendar to never miss important releases and spot opportunities early.
ABVX net income for the last quarter is ‪−117.43 M‬ EUR, while the quarter before that showed ‪−48.47 M‬ EUR of net income which accounts for −142.29% change.

How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result

Follow other essential metrics in Abivax SA financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
No, Abivax SA does not currently pay dividends to its shareholders.

Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.

What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends
ABVX reached its all-time high of 139.00 EUR on Jul 3, 2026. Its all-time low was 3.85 EUR and was reached on Aug 23, 2016.

Explore the Abivax SA stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Analyst forecasts suggest a price range between 70.00 EUR and 180.00 EUR for ABVX, based on current estimates.

Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions

Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance